331 related articles for article (PubMed ID: 22983922)
21. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
22. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
23. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
[TBL] [Abstract][Full Text] [Related]
24. Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma.
Luan Z; He Y; Alattar M; Chen Z; He F
Mol Cancer; 2014 Feb; 13():38. PubMed ID: 24568222
[TBL] [Abstract][Full Text] [Related]
25. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
26. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA
Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183
[TBL] [Abstract][Full Text] [Related]
27. Functional roles of Akt signaling in mouse skin tumorigenesis.
Segrelles C; Ruiz S; Perez P; Murga C; Santos M; Budunova IV; MartÃnez J; Larcher F; Slaga TJ; Gutkind JS; Jorcano JL; Paramio JM
Oncogene; 2002 Jan; 21(1):53-64. PubMed ID: 11791176
[TBL] [Abstract][Full Text] [Related]
28. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
29. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
30. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
31. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
32. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of ataxia-telangiectasia and Rad3-related protein by activated p21-activated kinase-1 protects keratinocytes in UV-B-induced premalignant skin lesions.
Beesetti S; Mavuluri J; Surabhi RP; Oberyszyn TM; Tober K; Pitani RS; Joseph LD; Venkatraman G; Rayala SK
Oncogene; 2017 Nov; 36(44):6154-6163. PubMed ID: 28692051
[TBL] [Abstract][Full Text] [Related]
34. An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening.
Nguyen AT; Emelyanov A; Koh CH; Spitsbergen JM; Parinov S; Gong Z
Dis Model Mech; 2012 Jan; 5(1):63-72. PubMed ID: 21903676
[TBL] [Abstract][Full Text] [Related]
35. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of PAK1 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells Through the ERK Pathway.
Wang S; Wang SY; Du F; Han Q; Wang EH; Luo EJ; Liu Y
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):602-610. PubMed ID: 31394555
[TBL] [Abstract][Full Text] [Related]
37. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
[TBL] [Abstract][Full Text] [Related]
39. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
40. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.
Deng M; Tang H; Zhou Y; Zhou M; Xiong W; Zheng Y; Ye Q; Zeng X; Liao Q; Guo X; Li X; Ma J; Li G
J Cell Sci; 2011 Sep; 124(Pt 17):2997-3005. PubMed ID: 21878506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]